Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
Välja arvatud juhul, kui ravi jätkamist angiotensiin II retseptori antagonistiga peetakse oluliseks, tuleb rasestumist planeeriv patsient üle viia alternatiivsele antihüpertensiivsele ravile, mille ohutuseprofiil raseduse ajal on tõestatud.